Molecular basis of agonism and antagonism in the oestrogen receptor
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Oestrogens are involved in the growth, development and homeostasis of a number of tissues. The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER). Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of molecular events culminating in the activation or repression of target genes. Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery. Here we report the crystal structures of the LBD of ER in complex with the endogenous oestrogen, 17beta-oestradiol, and the selective antagonist raloxifene, at resolutions of 3.1 and 2.6 A, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties. Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes. In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We previously found that the full-length ERα dimer forms a symmetric tail-to-tail dimer in the ERα/SRC-3/p300 complex (Yi et al., 2015), consistent with the nature of palindromic DNA binding sequence, symmetric X-ray crystal structures of the ERα LBD (Brzozowski et al., 1997) and DBD dimers (Schwabe et al., 1993).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
In the citing paper
“the AR LBD interacts weakly with LXXLL motif-containing coactivators, such as SRCs, (Brzozowski et al., 1997; Dubbink et al., 2006; He et al., 2004; He et al., 1999; Matias et al., 2000; Nadal et al., 2017).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · cited 1×
“Data were integrated and reduced using the programs DENZO and SCALEPAC”
MethodPROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions
Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.2.127 · Cited by 5,690
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932 · cited 1×
“The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER”
BackgroundThe estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,220 · cited 1×
“The ER LBDs are arranged as non-crystallographic dimers within both the E 2 and RAL complex crystals in a manner consistent with both the oligomeric state of liganded ER in solutio”
BackgroundCrystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/375377a0 · Cited by 1,177 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundCrystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid
Renaud, J.-P., Rochel, N., Ruff, M., Vivat, V., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/378681a0 · Cited by 1,097 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundA canonical structure for the ligand-binding domain of nuclear receptors
Wurtz, J.-M., Bourguet, W., Renaud, J.-P., Vivat, V., Chambon, P., Moras, D., & Gronemeyer, H. (1996) · Nature Structural Biology · doi:10.1038/nsb0196-87 · Cited by 985 · cited 1×
“, and emphasizes the universal nature of this fold within this receptor superfamil”
Background
Cited by
Items 401–500 of 1,012
Estrogen Receptor Dimerization: Ligand Binding Regulates Dimer Affinity and DimerDissociation Rate
Tamrazi, A., Carlson, K. E., Daniels, J. R., Hurth, K. M., & Katzenellenbogen, J. A. (2002) · Molecular Endocrinology · doi:10.1210/me.2002-0250 · Cited by 171
Potential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer
Peng, J., Sengupta, S., & Jordan, V. C. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009788451833 · Cited by 171
“The structural studies of a SERM complexed with the LBD of ERα and ERβ reveal that reorientation of the AF2 helix (helix 12) after the binding of the SERM to the hydrophobic pocket of the LBD [22, 23].”
InfluentialMizwicki, M. T., & Norman, A. W. (2009) · Science Signaling · doi:10.1126/scisignal.275re4 · Cited by 170
Hillisch, A., Peters, O., Kosemund, D., Müller, G., Walter, A., Schneider, B., Reddersen, G., Elger, W., & Fritzemeier, K.-H. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0050 · Cited by 170
“The position of H12 was modeled in the agonistic conformation as described for the hPR (human progesterone receptor)-LBD (23) and hER -LBD (24).”
BackgroundDistinct Roles of Unliganded and Liganded Estrogen Receptors in Transcriptional Repression
Cvoro, A., Tzagarakis-Foster, C., Tatomer, D., Paruthiyil, S., Fox, M. S., & Leitman, D. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.014 · Cited by 170
“A role for GRIP1 in E2-mediated repression was supported by the observation that no recruitment of GRIP1 occurred with tamoxifen, which is known to block p160 interactions with ER (Brzozowski et al., 1997; Shiau et al., 1998).”
BackgroundOestrogenic activity of isobutylparaben in vitro and in vivo
Darbre, P. D., Byford, J. R., Shaw, L. E., Horton, R. A., Pope, G. S., & Sauer, M. J. (2002) · Journal of Applied Toxicology · doi:10.1002/jat.860 · Cited by 170
“…and in which the physiological ligand 17β-oestradiol is positioned by hydrogen bonding of its 3- and 17-hydroxyl groups to amino acid side-chains, and by hydrophobic bonding (van der Waals forces) of the remainder of the steroid ring system to other amino acid side-chains (Brzozowski et al., 1997).”
BackgroundA dynamic mechanism of nuclear receptor activation and its perturbation in a human disease
Kallenberger, B. C., Love, J. D., Chatterjee, V. K. K., & Schwabe, J. W. R. (2003) · Nature Structural Biology · doi:10.1038/nsb892 · Cited by 170
Lonard, D. M., & Smith, C. S. (2002) · Steroids · doi:10.1016/s0039-128x(01)00133-7 · Cited by 170
An overview of current and emerging SERMs
Komm, B. S., & Mirkin, S. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.03.003 · Cited by 169
Jordan, V. C., Gapstur, S., & Morrow, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.19.1449 · Cited by 169
Antagonism in the humanmineralocorticoid receptor
Fagart, J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3317 · Cited by 169
“The hRARγ and the human estrogen receptor α-isoform (hERα) sequences (Renaud et al., 1995; Brzozowski et al., 1997), whose LBD crystal structures have been solved recently, are included in the alignment for comparison.”
BackgroundInfluentialMelatonin, an Endogenous-specific Inhibitor of Estrogen Receptor α via Calmodulin
del Río, B., Pedrero, J. M. G., Martínez-Campa, C., Zuazua, P., Lazo, P. S., & Ramos, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403140200 · Cited by 139
Suzuki, T., Kasahara, M., Yoshioka, H., Morohashi, K.-I., & Umesono, K. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.238-249.2003 · Cited by 154
“Interaction with ligand induces allosteric changes in conformation, especially in the configuration of helix 12 at the C terminus of the LBD, leading to transcriptional activation (3, 9) or repression (4, 57).”
BackgroundSladek, F. M., Ruse, M. D., Nepomuceno, L., Huang, S.-M., & Stallcup, M. R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.6509 · Cited by 130
“Structural studies have shown that this change makes a small conserved region important for transactivation in the C-terminal end of the LBD, termed AF-2, more accessible to solvent, and therefore presumably to coactivators ( 3 , 14, 73, 90).”
BackgroundFreeman, B. C., Felts, S. J., Toft, D. O., & Yamamoto, K. R. (2000) · Genes & Development · doi:10.1101/gad.14.4.422 · Cited by 168
“…ER and PR, those conformational effects alter hormone binding as well as transcriptional regulatory activity; such a result is not surprising, as a transcriptional activation domain resides within the ligand-binding domains of IRs (Brzozowski et al. 1997; Darimont et al. 1998; Shiau et al. 1998).”
BackgroundChapter 8: Estrogen Receptor-Mediated Processes in Normal and Cancer Cells
Dickson, R. B., & Stancel, G. M. (2000) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a024237 · Cited by 168
Molecular Determinants of the Estrogen Receptor-Coactivator Interface
Mak, H. Y., Hoare, S., Henttu, P. M. A., & Parker, M. G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3895 · Cited by 168
“Its importance in the ER is indicated by the observation that it is misaligned in the presence of an antiestrogen, raloxifene, which blocks AF2 activity (4).”
BackgroundCharles, G. D. (2000) · Toxicological Sciences · doi:10.1093/toxsci/55.2.320 · Cited by 168
“These demonstrated activities might be the consequence of the promiscuous binding capacity of the estrogen receptor, due to the structure of its binding cavity (Brzozowski et al., 1997).”
BackgroundWebb, P. (2000) · Molecular Endocrinology · doi:10.1210/me.14.12.1976 · Cited by 147
General Molecular Biology and Architecture of Nuclear Receptors
Pawlak, M., Lefebvre, P., & Staels, B. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436641 · Cited by 167
Visualization of macromolecular structures
O'Donoghue, S. I., Goodsell, D. S., Frangakis, A. S., Jossinet, F., Laskowski, R. A., Nilges, M., Saibil, H. R., Schafferhans, A., Wade, R. C., Westhof, E., et al. (2010) · Nature Methods · doi:10.1038/nmeth.1427 · Cited by 167
Hormone Selectivity in Thyroid Hormone Receptors
Wagner, R. L. (2001) · Molecular Endocrinology · doi:10.1210/me.15.3.398 · Cited by 167
“tamoxifen) show plasticity in H12 and the H11–H12 loop, with concomitant disruption of the H1–H3 loop (30, 31).”
BackgroundLee, Y., Escher, B. I., & von Gunten, U. (2008) · Environmental Science & Technology · doi:10.1021/es7023302 · Cited by 167
Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease
Khalil, R. A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.024 · Cited by 173
“With regard to hydrophobic interactions, the volume of the ER binding pocket is ~twice the size of E2, leading to large unoccupied cavities opposite C7α and C11β positions of E2 [58].”
BackgroundColeman, H. M., Routledge, E. J., Sumpter, J. P., Eggins, B. R., & Byrne, J. (2004) · Water Research · doi:10.1016/j.watres.2004.04.021 · Cited by 166
“Indeed, Ohko and colleagues previously reported that the photocatalysis reaction with E2 starts via oxidation of the phenol moiety [32], which is known to be critical for receptor binding and for conferral of estrogenicity to all steroid estrogens [33].”
BackgroundCrystallization of protein–ligand complexes
Hassell, A. M., An, G., Bledsoe, R. K., Bynum, J. M., Carter, H. L., Deng, S.-J. J., Gampe, R. T., Grisard, T. E., Madauss, K. P., Nolte, R. T., et al. (2007) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906047020 · Cited by 165
“This gave sufficient quantities of soluble protein without special growth conditions, i.e. inclusion of the ligand during protein expression (Brzozowski et al., 1997; Tanenbaum et al., 1998).”
Johnson, B. A., Wilson, E. M., Li, Y., Moller, D. E., Smith, R. G., & Zhou, G. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3636 · Cited by 165
Estrogen receptor β ligands: Recent advances and biomedical applications
Minutolo, F., Macchia, M., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2011) · Medicinal Research Reviews · doi:10.1002/med.20186 · Cited by 147
“A more indepth look at the ERa/ERb-binding cavities shows that each is composed of 23 residues that are within 4 Å of the ligand; of these 23, only at two positions are the amino acids different, and these differences represent conservative replacements: Leu384 and Met421 of ERa are, respectively, replaced by Met336 a…”
BackgroundBreast Cancer, Estrogen Receptor and Ligands
Bai, Z., & Gust, R. (2009) · Archiv der Pharmazie · doi:10.1002/ardp.200800174 · Cited by 166
Mewshaw, R. E., Edsall, R., Yang, C., Manas, E. S., Xu, Z. B., Henderson, R. A., Keith, J. C., & Harris, H. A. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058173s · Cited by 165
SUMNER, B. E. H., Grant, K. E., Rosie, R., Hegele-Hartung, C., Fritzemeier, K.-H., & Fink, G. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00243-0 · Cited by 166
Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice
Erlandsson, M., Jonsson, C., Lindberg, M., Ohlsson, C., & Carlsten, H. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750319 · Cited by 165
“A three-dimensional (3D) crystal structure of ERwith raloxifene bound displays how the conformation is changed compared with the 3D structure with E2 (Brzozowski et al. 1997).”
BackgroundEstrogen and estrogen receptors in kidney diseases
Ma, H.-Y., Chen, S., & Du, Y. (2021) · Renal Failure · doi:10.1080/0886022x.2021.1901739 · Cited by 164
“The E domain is identified as the ligand-binding domain (LBD) and the principal dimerization interface of the receptor, which contains a liganddependent activation function AF-2 [19,20].”
InfluentialSavory, J. G. A., Préfontaine, G. G., Lamprecht, C., Liao, M., Walther, R. F., Lefebvre, Y. A., & Haché, R. J. G. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.781-793.2001 · Cited by 163
“For ERa, biochemical and crystallographic studies have demonstrated that solution dimerization occurs through a motif at the C-terminal region of the LBD anchored by a-helix 10 but also involving helices 7, 8 and 9 (5, 18).”
BackgroundThe glucocorticoid receptor dimer interface allosterically transmits sequence-specific DNA signals
Watson, L. C., Kuchenbecker, K. M., Schiller, B. J., Gross, J. D., Pufall, M. A., & Yamamoto, K. R. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2595 · Cited by 163
“Structural studies of isolated nuclear receptor ligand binding domains (LBDs) suggest how signaling information residing in small molecule ligands is transmitted to a coregulator recognition surface 8,30–34 .”
Färnegårdh, M., Bonn, T., Sun, S., Ljunggren, J., Ahola, H., Wilhelmsson, A., Gustafsson, J.-Å., & Carlquist, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304842200 · Cited by 163
Self-citationDiscovery of diverse thyroid hormone receptor antagonists by high-throughput docking
Schapira, M., Raaka, B. M., Das, S., Fan, L., Totrov, M., Zhou, Z., Wilson, S. R., Abagyan, R., & Samuels, H. H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1131854100 · Cited by 163
Simoncini, T., Mannella, P., Fornari, L., Caruso, A., Willis, M. Y., Garibaldi, S., Baldacci, C., & Genazzani, A. R. (2004) · Endocrinology · doi:10.1210/en.2004-0510 · Cited by 163
“As happens for estrogen ligands (45), it is likely that the structural conformation of PR induced by distinct progestins may differ and that only seFIG.”
Huang, S., & Zou, X. (2006) · Journal of Computational Chemistry · doi:10.1002/jcc.20505 · Cited by 163
Phytoestrogens and Mycoestrogens Bind to the Rat Uterine Estrogen Receptor
Branham, W. S., Dial, S. L., Moland, C. L., Hass, B. S., Blair, R. M., Sheehan, D. M., Fang, H., Shi, L. M., Tong, W., & Perkins, R. (2002) · Journal of Nutrition · doi:10.1093/jn/132.4.658 · Cited by 163
Frasor, J., Chang, E. C., Komm, B., Lin, C.-Y., Vega, V. B., Liu, E. T., Miller, L. D., Smeds, J., Bergh, J., & Katzenellenbogen, B. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4269 · Cited by 162
Retinoic Acid Actions through Mammalian Nuclear Receptors
Huang, P., Chandra, V., & Rastinejad, F. (2014) · Chemical Reviews · doi:10.1021/cr400161b · Cited by 162
Stenoien, D. L., Nye, A. C., Mancini, M. G., Patel, K., Dutertre, M., O'Malley, B. W., Smith, C. L., Belmont, A. S., & Mancini, M. A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4404-4412.2001 · Cited by 149
“In contrast, helix 12 in the raloxifenebound LBD is buried in a hydrophobic groove that limits access to critical residues required for AF-2 function.”
BackgroundInfluentialMolecular mechanisms of steroid hormone action
White, R. (1998) · Endocrine Related Cancer · doi:10.1677/erc.0.0050001 · Cited by 138
“…structure of the ligand binding domain of several receptors have been determined (Bourguet et al. 1995, Renaud et al. 1995, Wagner et al. 1995, Brzozowski et al. 1997) and secondly, novel proteins have been identified (Cavaillès et al. 1994, Halachmi et al. 1994) which interact with receptors…”
BackgroundA New Series of Estrogen Receptor Modulators That Display Selectivity for Estrogen Receptor β
Henke, B. R., Consler, T. G., Go, N., Hale, R. L., Hohman, D. R., Jones, S. A., Lu, A. T., Moore, L. B., Moore, J. T., Orband-Miller, L. A., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020291h · Cited by 161
Effects of Arsenite on Estrogen Receptor-α Expression and Activity in MCF-7 Breast Cancer Cells1
Stoica, A., Pentecost, E., & Martin, M. B. (2000) · Endocrinology · doi:10.1210/endo.141.10.7704 · Cited by 144
Sumoylation of the Progesterone Receptor and of the Steroid Receptor Coactivator SRC-1
Chauchereau, A., Amazit, L., Quesne, M., Guiochon-Mantel, A., & Milgrom, E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207148200 · Cited by 142
Clayton, G. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041611298 · Cited by 153
Conformational adaptation of agonists to the human nuclear receptor RARγ
Klaholz, B. P., Renaud, J., Mitschler, A., Zusi, C., Chambon, P., Gronemeyer, H., & Moras, D. (1998) · Nature Structural Biology · doi:10.1038/nsb0398-199 · Cited by 161
Nikov, G. N., Hopkins, N. E., Boue, S., & Alworth, W. L. (2000) · Environmental Health Perspectives · doi:10.1289/ehp.00108867 · Cited by 160
“The length and the width of the E2 skeleton are very well matched by the receptor’s ligand binding domain, but there are large unoccupied spaces opposite the B-ring and the Cring of E2 (31).”
BackgroundLigand selectivity by seeking hydrophobicity in thyroid hormone receptor
Borngraeber, S., Budny, M.-J., Chiellini, G., Cunha-Lima, S. T., Togashi, M., Webb, P., Baxter, J. D., Scanlan, T. S., & Fletterick, R. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2136689100 · Cited by 160
Ecdysone Receptors: From the Ashburner Model to Structural Biology
Hill, R. J., Billas, I. M. L., Bonneton, F., Graham, L. D., & Lawrence, M. C. (2013) · Annual Review of Entomology · doi:10.1146/annurev-ento-120811-153610 · Cited by 160
“The “activation” helix, H12, of the EcR LBD (also called activation function region 2, AF-2) is positioned in all structures in the so-called agonist conformation (23) that exposes the coactivator binding site (a conserved hydrophobic groove formed on the surface of the receptor by residues within helices H3 and H4).”
Background6H-Benzo[c]chromen-6-one derivatives as selective ERβ agonists
Sun, W., CAMA, L. D., Birzin, E. T., Mitra, S. W., Locco, L., Mosley, R., Hammond, M. L., & Rohrer, S. P. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.12.057 · Cited by 160
Estrogen receptor corepressors -- a role in human breast cancer?
Dobrzycka, K. M., Townson, S. M., Jiang, S., & Oesterreich, S. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100517 · Cited by 161
“stood in considerable detail (Brzozowski et al. 1997).”
BackgroundDeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
Li, F., Hu, Q., Zhang, X., Sun, R., Liu, Z., Wu, S., Tian, S., Ma, X., Dai, Z., Yang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34807-3 · Cited by 159
“The long linker in PROTAC 10 results in a parallel conformation of ternary complex, in which the interactions (ER-VHL: E380-Q96, R515-Q195, R434-E173) occur mostly between VHL and H8/H11 helices of ER.”
BackgroundInfluentialClinical Effects of Raloxifene Hydrochloride in Women
Khovidhunkit, W., & Shoback, D. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00015 · Cited by 159
Llopis, J., Westin, S., Ricote, M., Wang, J., Cho, C. Y., Kurokawa, R., Mullen, T.-M., Rose, D. W., Rosenfeld, M. G., Tsien, R. Y., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4363 · Cited by 139
Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-α activity
Thomas, R. S., Sarwar, N., Phoenix, F. A., Coombes, R. C., & Ali, S. (2008) · Journal of Molecular Endocrinology · doi:10.1677/jme-07-0165 · Cited by 159
“Tamoxifen is an example of a mixed estrogen agonist/antagonist, also termed selective ERmodulators, which has been proposed to act by inhibiting the LBD/AF-2, whilst allowing activation of AF-1 (Berry et al. 1990, McDonnell et al. 1995, Brzozowski et al. 1997, Shiau et al. 1998).”
BackgroundInfluentialSteketee, K., Timmerman, L., Ziel‐van der Made, A. C. J., Doesburg, P., Brinkmann, A. O., & Trapman, J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10495 · Cited by 139
Oestrogenic activity of benzylparaben
Darbre, P. D., Byford, J. R., Shaw, L. E., Hall, S., Coldham, N. G., Pope, G. S., & Sauer, M. J. (2003) · Journal of Applied Toxicology · doi:10.1002/jat.886 · Cited by 158
“Such an aromatic ring could be expected to show chemical bonding to the amino acid side-chains present within the ligand binding domain of the ER (Brzozowski et al., 1997), which is different from that shown by the alkyl groups of the parabens studied previously in this laboratory (Byford et al.”
BackgroundSelective androgen receptor modulators in preclinical and clinical development
Narayanan, R., Mohler, M. L., Bohl, C. E., Miller, D. D., & Dalton, J. T. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06010 · Cited by 158
“, R1881, DHT) are the same [Bohl et al., 2005b; Brzozowski et al., 1997; Matias et al., 2000; Sack et al., 2001; Tanenbaum et al., 1998; Wang et al., 2006].”
A structural biologist's view of the oestrogen receptor
Pike, A. C. W., Brzozowski, A. M., & Hubbard, R. E. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00102-3 · Cited by 158
Self-citationJanvilisri, T., Venter, H., Shahi, S., Reuter, G., Balakrishnan, L., & van Veen, H. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301358200 · Cited by 158
Estrogen Biosynthesis and Action in Ovarian Cancer
Mungenast, F., & Thalhammer, T. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00192 · Cited by 158
“This may be an advantage for receptor subtype specific drugs (76, 77).”
BackgroundMorani, A., Warner, M., & Gustafsson, J. ‐. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01976.x · Cited by 132
Self-citationSelectively targeting estrogen receptors for cancer treatment
Shanle, E. K., & Xu, W. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.001 · Cited by 158
“Unlike many nuclear receptors, the hydrophobic core in the LBD of estrogen receptor is relatively larger than the endogenous ligand 17β-estradiol (E2), which allows the receptor to bind a variety of small molecules, some of which are presented in Table 1 [61,62].”
BackgroundHodgson, M. C., Astapova, I., Cheng, S., Lee, L. J., Verhoeven, M. C., Choi, E., Balk, S. P., & Hollenberg, A. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408972200 · Cited by 144
Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention
Park, W., & Jordan, V. C. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02282-7 · Cited by 160
Bekele, R. T., Venkatraman, G., Liu, R.-Z., Tang, X., Mi, S., Benesch, M. G. K., Mackey, J. R., Godbout, R., Curtis, J. M., McMullen, T. P. W., et al. (2016) · Scientific Reports · doi:10.1038/srep21164 · Cited by 148
Thyroid Receptor Ligands. 1. Agonist Ligands Selective for the Thyroid Receptor β1
Ye, L., Li, Y.-L., Mellström, K., Mellin, C., Bladh, L.-G., Koehler, K., Garg, N., Garcia Collazo, A. M., Litten, C., Husman, B., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021080f · Cited by 143
Different glucocorticoids vary in their genomic and non‐genomic mechanism of action in A549 cells
Croxtall, J. D., Van Hal, P. T. W., Choudhury, Q., Gilroy, D. W., & Flower, R. J. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704474 · Cited by 148
“Whether GCs are able to di erentially in¯uence GR structure in a manner analagous to that which has already been established for oestrogen antagonists upon ER (Brzozowski et al., 1997) remains to be determined.”
BackgroundMolecular aspects of phytoestrogen selective binding at estrogen receptors
Turner, J., Agatonović-Kuštrin, S., & Glass, B. D. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20987 · Cited by 157
Characterization of oestrogen receptors in zebrafish (Danio rerio)
Bardet, P., Horard, B., Robinson‐Rechavi, M., Laudet, V., & Vanacker, J.-M. (2002) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0280153 · Cited by 158
Malekinejad, H., Schoevers, E. J., Daemen, I., Zijlstra, C., Colenbrander, B., Fink‐Gremmels, J., & Roelen, B. A. J. (2007) · Biology of Reproduction · doi:10.1095/biolreprod.107.062711 · Cited by 157
“Binding of estradiol to ESR1 occurs via the aromatic ring of estradiol, but the volume of the binding pocket of the receptor is almost twice as large as estradiol, presumably allowing the acceptance of a number of different nonsteroidal compounds, such as ZEA [2].”
BackgroundThe Nuclear Xenobiotic Receptor Pregnane X Receptor: Recent Insights and New Challenges
Orans, J., Teotico, D. G., & Redinbo, M. R. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0156 · Cited by 156
Selective oestrogen receptor modulation
Levenson, A. S., & Jordan, V. C. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00297-x · Cited by 157
Leeuwen, I. J. D. V.-V., Pereira, D. D. C., Flach, K. D., Piersma, S. R., Haase, C., Bier, D., Yalçin, Z., Michalides, R. J. A. M., Feenstra, K. A., Jiménez, C. R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220809110 · Cited by 155
“17β-Estradiol (E2) association with the ERα ligand binding domain (LBD) drives large conformational changes (10) resulting in ERα dissociation from chaperones (11, 12), unmasking of domains for receptor dimerization, and DNA binding (13, 14).”
BackgroundHovland, A. R., Powell, R. L., Takimoto, G. S., Tung, L., & Horwitz, K. B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5455 · Cited by 144
Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes
Yu, X., Yi, P., Hamilton, R. A., Shen, H., Chen, M., Foulds, C. E., Mancini, M. A., Ludtke, S. J., Wang, Z., & O’Malley, B. W. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.031 · Cited by 154
Enzymatic determination of BPA by means of tyrosinase immobilized on different carbon carriers
Mita, D. G., Attanasio, A., Arduini, F., Diano, N., Grano, V., Bencivenga, U., Rossi, S., Amine, A., & Moscone, D. (2007) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2007.03.010 · Cited by 154
Potent Estrogenic Agonists Bearing Dicarba-closo-dodecaborane as a Hydrophobic Pharmacophore
Endo, Y., Iijima, T., Yamakoshi, Y., Yamaguchi, M., Fukasawa, H., & Shudo, K. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9900725 · Cited by 154
Delage-Mourroux, R., Martini, P. G. V., Choi, I., Kraichely, D. M., Hoeksema, J., & Katzenellenbogen, B. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001327200 · Cited by 142
Hawkins, M. B., & Thomas, P. (2004) · Endocrinology · doi:10.1210/en.2003-0806 · Cited by 132
A structural perspective on nuclear receptors as targets of environmental compounds
Delfosse, V., Maire, A. L., Balaguer, P., & Bourguet, W. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.133 · Cited by 136
Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix
Gampe, R. T., Montana, V. G., Lambert, M. H., Wisely, G. B., Milburn, M. V., & Xu, H. E. (2000) · Genes & Development · doi:10.1101/gad.802300 · Cited by 153
“Crystal structures of either apo- or ligand-bound LBDs have been determined for several NRs (Bourguet et al. 1995; Renaud et al. 1995; Wagner et al. 1995; Brzozowski et al. 1997; Nolte et al. 1998; Williams and Sigler 1998; Xu et al. 1999).”
BackgroundStructural plasticity in the oestrogen receptor ligand‐binding domain
Nettles, K. W., Bruning, J. B., Gil, G., O'Neill, E. E., Nowak, J., Hughs, A., Kim, Y., DeSombre, E. R., Dilis, R., Hanson, R. N., et al. (2007) · EMBO reports · doi:10.1038/sj.embor.7400963 · Cited by 137
“So far, X-ray crystal structures of ER ligands with bulky side chains have all been shown to protrude from the ligand-binding cavity and act as antagonists by displacement of helix 12 (Brzozowski et al, 1997; Shiau et al, 1998; Pike et al, 2001; Blizzard et al, 2005).”
BackgroundSelf-citationThyroxine-thyroid hormone receptor interactions
Sandler, B., Webb, P., Apriletti, J. W., Huber, B. R., Togashi, M., Lima, S. T. C., Juric, S., Nilsson, S., Wagner, R., Fletterick, R. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410124200 · Cited by 152
Saponins as modulators of nuclear receptors
Zhang, T., Zhong, S., Li, T., & Zhang, J. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1514580 · Cited by 153
Beck, I., Bruhn, R., & Gandrass, J. (2005) · Chemosphere · doi:10.1016/j.chemosphere.2005.10.022 · Cited by 152
“All rights reserved. doi:10.1016/j.chemosphere.2005.10.022 Their ability to interact with the human estrogen receptor a (hERa) is due to the large gap in the receptorsÕ ligand-binding domain (Brzozowski et al., 1997).”
BackgroundInfluentialDifferential SERM Effects on Corepressor Binding Dictate ERα Activity in Vivo
Webb, P., Nguyen, P., & Kushner, P. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208501200 · Cited by 139
Rodriguez, A. L., Tamrazi, A., Collins, M. L., & Katzenellenbogen, J. A. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030404c · Cited by 152
Lee, D. K., Duan, H. O., & Chang, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002285200 · Cited by 135
Estrogen signaling: An emanating therapeutic target for breast cancer treatment
Saha, T., Makar, S., Swetha, R., Gutti, G., & Singh, S. K. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.023 · Cited by 134
Amari, S., Aizawa, M., Zhang, J., Fukuzawa, K., Mochizuki, Y., Iwasawa, Y., Nakata, K., Chuman, H., & Nakano, T. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci050262q · Cited by 151
Genistein—A dietary compound inducing hormonal and metabolic changes
Szkudelska, K., & Nogowski, L. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.01.005 · Cited by 151
Bièche, I., Parfait, B., Doussal, V. L., Olivi, M., Rio, M. C., Lidereau, R., & Vidaud, M. (2001) · PubMed · Cited by 151
Brinkman, A., van der Flier, S., Kok, E. M., & Dorssers, L. C. J. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.2.112 · Cited by 146
“... genes (3‐6).In approximately two thirds of all breast tumors, the estrogen receptor (ER) is present and functionally active (7‐9).The presence of the ER in breast carcinoma cells and their responsiveness to estrogens is clinically exploited by the administration of antagonists of estrogens or antiestrogens (10‐12)…”
BackgroundIntrinsically disordered proteins and multicellular organisms
Dunker, A. K., Bondos, S. E., Huang, F., & Oldfield, C. J. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.09.025 · Cited by 150
Estrogen Receptor Signaling in Lung Cancer
Siegfried, J. M., Hershberger, P. A., & Stabile, L. P. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.10.004 · Cited by 135
Connor, C. E., Norris, J. D., Broadwater, G., Willson, T. M., Gottardis, M. M., Dewhirst, M. W., & McDonnell, D. P. (2001) · PubMed · Cited by 150
Metadata
- Authors
- Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M.
- Affiliations
- University of York (GB)
- Karo Pharma (Sweden) (SE)
- University of Chicago (US)
- Corresponding author
- Hubbard, Roderick E.
- ORCID
- Venue
- Nature
- Published
- 1997-10
- Volume
- 389
- Issue
- 6652
- Pages
- 753-758
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2101738855
- Cited by
- 3,355
- References
- 29
- Citations by year
- 2026: 49 · 2025: 55 · 2024: 55 · 2023: 61 · 2022: 62 · 2021: 91 · 2020: 55 · 2019: 75 · 2018: 73 · 2017: 65 · 2016: 72 · 2015: 74 · 2014: 94 · 2013: 105 · 2012: 104
- FWCI
- 94.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- oestrogen receptor, ligand-binding domain, estradiol, raloxifene, selective estrogen receptor modulators, crystal structure, transcriptional regulation
- MeSH terms
- Binding Sites, Estradiol, Estrogen Antagonists, Humans, Models, Molecular, Piperidines, Protein Conformation, Receptors, Estrogen, Crystallography, X-Ray, Raloxifene Hydrochloride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.